1. Aide
    1. Espace Client
    2. Connexion
Espace Membre Boursorama

Erreur d'authentification

Vous êtes authentifié. Nous chargeons votre espace membre.

Mot de passe oublié ?

Nouveau sur Boursorama ? Devenez membre

Identifiant/Mot de passe oublié
Si vous êtes Membre de la Communauté Boursorama, veuillez indiquer l'adresse email que vous avez fournie lors de votre enregistrement pour recevoir votre identifiant et/ou ré-initialiser votre mot de passe :

Nouveau sur Boursorama ? Devenez membre


Transgene: First Quarter 2013 Financial Report
Boursorama22/04/2013 à 19:45



First Quarter 2013 Financial Report 




Strasbourg, France, April 22, 2013 Transgene (Euronext Paris: FR0005175080) today issues its quarterly financial report as of March 31, 2013 (first quarter of 2013).



The following table summarizes the first quarter operating revenue[1] for 2013 compared to the same period in 2012:



In thousands of euros

  Q1 2013     

Q1 2012

Revenue from collaborative and licensing agreements



Government financing for research expenditures



Operating revenue




During the first quarter of 2013, revenue from collaborative and licensing agreements were principally composed of: (i) manufacturing services for Jennerex, Inc., strategic partner of Transgene for the development of JX594/TG6006, (ii) revenue from the payment made in 2010 by Novartis for the exclusive option agreement on TG4010, and (iii) royalty from technologies or products licensed by Transgene.

As of March 31, 2013, government financing for research expenditures corresponds to: (i) an estimate of the income accrued during the period for subsidies received and/or to be received (839 thousands of euros), and (ii) a quarter of the research tax credit expected for 2013 (2 million euros).


Cash, Cash Equivalents, Available-for-sale Financial Assets and other Financial Assets:

Cash, cash equivalents, available-for-sale financial assets and other financial assets amounted to 80.1 million euros as of March 31, 2013, compared to 92.9 million euros as of December 31, 2012. Consumption of cash[2] amounted to 12.8 million euros in the first quarter of 2013, to be compared with 15.7 million euros in the first quarter of 2012. Transgene expects a cash consumption of around 50 million euros in 2013.


About Transgene:

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for the treatment of cancers and infectious diseases. Transgenes products are major technological breakthroughs. They use well tolerated viruses to indirectly or directly kill infected or cancerous cells. Its four most advanced products have generated proof of concept data in randomized clinical studies: in lung cancer (TG4010), liver cancer (Pexa-Vec), hepatitis C (TG4040) and HPV-related cervical lesions (TG4001). Transgene has concluded strategic agreements for the development of three of these products: an option agreement with Novartis for the development of TG4010, an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec and a strategic collaboration with EORTC to develop TG4001 in cancer of the oropharynx. Transgene also has a non-exclusive agreement with Sanofi/Genzyme for its future commercial production. With 280 employees, it is based in Strasbourg, France, and has operations in Lyon, China and the USA. Additional information about Transgene is available at www.transgene.fr.


Transgene Forward Looking Statements:

This press release contains forward-looking statements notably referring to an anticipated future BLA filing date by Transgene. Such anticipated future BLA filing date is based on the current plan of product development and testing. This plan may change in the future and, as such, Transgene could be in a position not to meet the currently anticipated development milestones, including such BLA filing. For further information on the risks and uncertainties involved in the testing and development of Transgenes product candidates, see Trangenes Document de Référence on file with the French Autorité des marchés financiers on its website at http://www.amffrance.org and on Transgenes website at www.transgene.fr .





Philippe Archinard, Chairman & CEO, +33 (0)3 88 27 91 22

Stéphane Boissel, Executive Vice President & CFO, +33 (0)3 88 27 91 02

Elisabetta Castelli, Director IR, +33 (0)3 88 27 91 21


MC Services

Raimund Gabriel, +49 89 210 228 30

Shaun Brown, +44 207 148 5998




[1] Unaudited and not subject to approval by the Board of Directors.

[2]Cash, cash equivalents, available-for-sale financial assets and other financial assets.








Valeurs associées

Euronext Paris 0.00%

0 commentaire

Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement

Signaler le commentaire


Mes listes

Une erreur est survenue pendant le chargement de la liste




5591.69 0.00%
1.766 0.00%
1.12054 -0.17%
22.94 0.00%
2.38 0.00%

Les Risques en Bourse